Understanding MDS/MPN-RS-T
An overlap blood disorder combining dysplastic anemia with ring sideroblasts and a persistently high platelet count, most often driven by SF3B1 mutations.
- Overlap MDS/MPN entity
- SF3B1-associated
- Often indolent course
- Disease Group
- MDS/MPN Overlap
- Key Mutation
- SF3B1 (>80%)
- Typical Onset
- Older Adults
- Course
- Often Indolent
- Advanced Therapies
- Trial Access
Condition Overview
MDS/MPN-RS-T is a rare clonal blood disorder that sits between myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It combines dysplastic, ring-sideroblast-containing red cell precursors with a sustained elevated platelet count, reflecting overlapping marrow features of both disease families.
Types and Subtypes
Classification is based on the molecular drivers present alongside the SF3B1 mutation.
Symptoms and Signs
Many patients are diagnosed incidentally on routine blood counts; others present with anemia-related or thrombotic symptoms.
Causes and Risk Factors
MDS/MPN-RS-T arises from acquired (not inherited) mutations in blood stem cells.
Diagnosis and Investigations
Diagnosis requires a combination of blood counts, bone marrow examination, and molecular testing.
Staging and Risk Groups
Rather than formal staging, patients are stratified by molecular and clinical risk features that guide monitoring intensity and treatment decisions.
Standard Treatment
Treatment is individualized and depends on whether anemia, thrombocytosis, or thrombotic risk dominates the clinical picture.
Advanced & Emerging Therapies
Several newer agents are being explored or used off-label for SF3B1-mutant overlap syndromes.
Erythroid Maturation Agent
Luspatercept
Approved for SF3B1-associated lower-risk MDS-related anemia; explored in MDS/MPN-RS-T to reduce transfusion needs.
JAK Inhibitor
Ruxolitinib
Investigated for symptomatic splenomegaly in JAK2-mutated overlap cases.
Clinical Trial
Splicing Modulator Studies
Trials targeting SF3B1-mutant clones are an active area of research relevant to this condition.
Biomarkers & Precision Medicine
Molecular testing guides both diagnosis and risk stratification.
When to Seek a Second Opinion
Given the rarity of this overlap entity, expert hematopathology review is valuable at several points.
Clinical Trials & Research
Prognosis & Outcomes
Many patients have a prolonged, relatively stable course, though outcomes vary based on molecular profile and disease evolution.
Supportive Care
Supportive measures help manage symptoms and reduce complication risk alongside disease-directed treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with MDS/MPN-RS-T get expert hematopathology review of bone marrow and molecular results, and connect with specialists experienced in rare overlap blood disorders.
Get a free case reviewFrequently Asked Questions
It is a rare overlap blood disorder combining features of myelodysplastic syndrome (ring sideroblasts, dysplasia) with a myeloproliferative neoplasm (persistently elevated platelet count), most commonly driven by an SF3B1 mutation.
It is a clonal blood disorder classified within the myeloid neoplasm spectrum; it is generally less aggressive than acute leukemia but requires ongoing hematology monitoring.
It results from acquired mutations, most commonly SF3B1 together with JAK2 or CALR, in blood-forming stem cells; it is not inherited.
Diagnosis combines blood counts showing anemia with thrombocytosis, bone marrow biopsy showing ring sideroblasts, and molecular testing for SF3B1 and JAK2/CALR mutations.
No. Many patients with stable, low-risk disease are monitored without immediate treatment, while others need therapy for anemia or thrombosis risk.
Options range from observation to erythropoiesis-stimulating agents, luspatercept, cytoreductive drugs, and in some cases hypomethylating agents, chosen based on individual risk.
Progression to acute myeloid leukemia is uncommon but possible, particularly in patients with high-risk molecular features; regular monitoring helps detect changes early.
Yes, the thrombocytosis component carries some thrombotic risk, which is why aspirin or cytoreductive therapy is considered in higher-risk patients.
Given the rarity of this entity, trial options are often accessed through broader MDS/MPN or SF3B1-targeted studies; a specialist center can help identify relevant trials.
Yes. CancerFax can help review your bone marrow and molecular reports, coordinate a second opinion with hematology specialists, and explore advanced therapy or clinical trial access, including international coordination where relevant.
Get Expert Guidance on Your Diagnosis
Share your reports for a structured review and explore second opinion and advanced therapy options.